Skip to main content

Table 5 Intensities of the peaks for different categories of the tumor characteristics

From: Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study

   M/z4276 M/z4292 M/z8129 M/z8941
  n Median intensity
(IQR)
Median intensity
(IQR)
Median intensity
(IQR)
Median intensity
(IQR)
TNM stage      
   IIA 26 13.00
(1.79–83.10)
19.51
(8.07–54.23)
26.27
(23.48–30.07)
33.56
(24.09–50.43)
   IIB 10 4.97
(1.33–17.24)
11.44
(4.83–15.79)
25.44
(16.56–27.75)
30.49
(20.16–34.59)
   III 11 11.88
(4.89–24.69)
15.86
(9.88–22.87)
25.70
(15.68–26.54)
37.55
(25.26–47.29)
p-value* 47 .340 .211 .203 .473
p-trend# 47 .553 .368 .075 .667
Tumor size      
   0.5–2 cm 18 10.24
(1.36–85.58)
18.44
(5.44–63.09)
26.53
(22.86–30.08)
30.48
(23.24–61.21)
   > 2 cm 29 11.88
(3.97–24.51)
12.21
(8.71–24.28)
25.90
(19.08–27.45)
32.90
(24.04–44.16)
p-value 47 .844 .526 .204 .896
Lymph node involvement      
   No 9 24.34
(5.99–72.28)
25.69
(9.91–54.35)
26.48
(23.33–30.29)
38.92
(27.68–53.99)
   Yes 38 8.66
(1.87–24.37)
13.13
(5.97–23.74)
25.81
(18.87–27.65)
30.49
(23.30–43.31)
p-value 47 .137 .144 .224 .224
Differentiation      
   High-Intermediate 25 11.04
(2.99–24.47)
14.06
(7.86–22.52)
25.72
(19.84–27.45)
31.27
(24.13–42.65)
   Low 21 19.90
(2.98–60.12)
17.06
(8.71–44.18)
26.54
(19.68–29.79)
28.99
(23.34–45.88)
p-value 46 .635 .384 .360 .903
  1. M/z = Mass to Charge ratio, IQR = Inter-Quartile Range, * Kruskal Wallis Test, # Jonckheere-Terpstra Test, Mann-Whitney U Test